00:34 , Jun 9, 2017 |  BC Extra  |  Clinical News

Team describes off-target effects of Bial's FAAH inhibitor

In a paper published in Science, researchers characterized off-target activities of fatty acid amide hydrolase (FAAH) inhibitor BIA 10-2474 that they say may have played a role in the compound’s clinical neurotoxicity that led to...
07:00 , Aug 12, 2016 |  BC Extra  |  Clinical News

FDA: Bial-Portela's FAAH inhibitor has "unique toxicity"

In its safety review of fatty acid amide hydrolase ( FAAH) inhibitors, FDA concluded that BIA 10-2474 from Bial-Portela & Ca. S.A. (S. Mamede do Coronado, Portugal) "exhibits a unique toxicity that does not extend...
03:21 , Mar 11, 2016 |  BC Extra  |  Politics & Policy

French group outlines first-in-man trial precautions

A special committee created by the French National Agency for Medicines and Health Products Safety (ANSM) made initial recommendations for first-in-man trials following a death and several hospitalizations of healthy volunteers in a Phase I...
08:00 , Feb 1, 2016 |  BC Week In Review  |  Clinical News

BIA 10-2474: Phase I halted

The French Health Ministry said a placebo-controlled, French Phase I trial of the oral analgesic BIA 10-2474 in 116 healthy volunteers has been halted after 6 subjects were hospitalized with serious “neurological troubles,” including 1...
01:51 , Jan 21, 2016 |  BC Extra  |  Clinical News

Janssen halts trials of FAAH inhibitor

The Janssen Research & Development LLC unit of Johnson & Johnson suspended dosing of fatty acid amide hydrolase ( FAAH) inhibitor JNJ-42165279 in two Phase II trials. The decision follows the death of a healthy...
02:34 , Jan 16, 2016 |  BC Extra  |  Clinical News

One volunteer brain-dead in Bial trial

The French Health Ministry said a Phase I trial of the oral analgesic BIA 10-2474 from Bial-Portela & Ca. S.A. (S. Mamede do Coronado, Portugal) has been halted after several healthy volunteers were hospitalized with...